



Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Tz and RA also reduce cell migration in the presence of FAK inhibitor. (A-C) SKBR3 and (D-F) BT-474 cells were grown in 96-well plates until they formed a monolayer; then, a “wound” was made. The treatments, in the presence of FAK inhibitor (FAKi), were performed for 72 h; cell migration was monitored by taking photographs. (A, D) 24 h (B, E) 48 h (C, F) 72 h of treatment. Gap closure was quantified with the use of NIH image J software. Experiments were performed in triplicate. *P < 0.05 vs. Control (Con).



Supplementary Figure 2: Tz and RA also reduce cell migration in the presence of specific FAK siRNA. (A-C) SKBR3 and (D-F) BT-474 cells were grown in 96-well plates until they formed a monolayer; then, a “wound” was made. The treatments, in the presence of specific FAK siRNA, were performed for 72 h; cell migration was monitored by taking photographs. (A, D) 24 h (B, E) 48 h (C, F) 72 h of treatment. Gap closure was quantified with the use of NIH image J software. Experiments were performed in triplicate. *P <0.05 vs. Control (Con).